Mirum Raised Its 2026 Sales View to $700M-But One FDA Split Could Decide the Next Leg Higher

Commercial momentum changed the near-term setup

Stronger sales gave Mirum more room to wait

Mirum's core business is doing what it needs to do. The company reported Q2 net product sales of $176.2 million and raised 2026 net product sales guidance to $680 million-$700 million. That gives Mirum more breathing room than it had a year ago, which helps explain why investors are now focused less on the current sales run-rate and more on whether pipeline progress can become a second revenue engine.

FDA feedback still sets the timetable

The bigger near-term question is volixibat in PSC. Mirum now targets a potential NDA submission in the first half of 2027 after the FDA recommended an additional Phase III study. Management disagrees that another trial is needed and plans further discussions with the agency, but the practical effect is the same: the next major catalyst is delayed rather than resolved.

That also means the bullish case is more conditional than it was before the quarter. The commercial base supports the wait, but the next repricing event still depends on regulatory execution.

Volixibat in PSC is the real debate: filing now, or filing later?

This is not mainly a debate about whether volixibat has biological activity. It is a debate about whether Mirum has enough existing evidence to support a filing, or whether the FDA still wants more certainty.

What the FDA disagreement means

In practical terms, the FDA has asked for one more Phase 3 study before it would consider a filing for volixibat in PSC, and Mirum says that is unnecessary FDA recommended an additional Phase III studyMirum disagrees that another trial is needed. Management still plans further discussions with the FDA before a potential NDA submission. That makes this a regulatory negotiation, not a straightforward approval timeline.

That distinction matters. The discussion could end with Mirum completing the extra study, persuading the FDA to rely on the existing data package, or reaching an impasse that weakens the filing outlook. For investors, the key question is not just whether the data look promising, but whether the company and the agency are moving toward a filing strategy both can accept.

Why bulls still have a case

Mirum is not coming to this discussion empty-handed. The company can point to a data package that includes VISTAS efficacy data from more than 180 randomized PSC patients, along with meaningful safety exposure. It also has regulatory support to lean on: the FDA granted volixibat Breakthrough Therapy and Orphan Drug Designations for cholestatic pruritus due to PSC.

There is also a second pillar starting to take shape. The VANTAGE Phase 3 study in PBC has completed enrollment with more than 330 patients, and FDA feedback indicates it may serve as a pivotal study if the first-quarter 2027 results are successful. If VANTAGE succeeds, Mirum will have more leverage in the PSC discussion because it will not be relying on a single disputed program.

Why bears still have a case

Bears do not need to argue that volixibat lacks activity. They only need to argue that regulatory process can still matter as much as biology. If the FDA holds its position on wanting an additional Phase 3 study, the asset's value is still exposed to delays, extra costs, and filing uncertainty.

That is why this stage of the story is really about clarity. Investors do not just need more data; they need a clearer answer on whether Mirum can turn a disagreement into an acceptable filing strategy.

What would change the story from here

From here, the stock should move less on generic progress language and more on milestones that change the odds or timing of commercialization.

The next repricing gates

Bullish reset: - FDA guidance improves after Mirum's planned further discussions with the FDA before a potential NDA submission. - VANTAGE lands on schedule and looks pivotal enough to carry more of the volixibat case if the first-quarter 2027 results are successful. - Zilurgisertib keeps its approval path intact around the September PDUFA date, showing Mirum can still execute on a new launch.

Invalidation: - The PSC dispute hardens into a firm demand for another trial, leaving the potential NDA stuck in the first half of 2027 without a clearer workaround. - VANTAGE misses or underwhelms, leaving Mirum short of a second regulatory pillar data expected Q1 2027. - Zilurgisertib stumbles before the September 26, 2026 PDUFA date, turning the story back into a funding-and-patience test rather than an upside narrative.